News

Filter

Current filters:

BayerDiabetes

26 to 35 of 95916 results

Call for Indian govt to bring more essential drugs under price control from NGOs

Call for Indian govt to bring more essential drugs under price control from NGOs

22-08-2014

Non-governmental organizations in India have jointly issued a letter calling on the country’s government…

Cardio-vascularDiabetesIndiaNational Pharmaceuticals Pricing AuthorityPharmaceuticalPoliticsPricing

EXPERT VIEW: Pay-for-delay - GSK’s wait is almost over…

EXPERT VIEW: Pay-for-delay - GSK’s wait is almost over…

22-08-2014

If GlaxoSmithKline thought that the demise of the Office of Fair Trading (OFT) on April 1 would bring…

Activist UK LimitedGenericsGlaxoSmithKlineLicensingPatentsPharmaceuticalSeroxatUK

ADHD treatment market set to reach $9.9 billion by 2020

ADHD treatment market set to reach $9.9 billion by 2020

22-08-2014

The attention-deficit hyperactivity disorder (ADHD) therapeutics market value will rise from $6.9 billion…

ADHDEuropeJapanNeurologicalPharmaceuticalPsychiatryUSA

Insulin offers new hope for the treatment of acute pancreatitis

22-08-2014

Acute pancreatitis involves the pancreas digesting itself resulting in severe abdominal pain, vomiting…

DiabetesInflammatory diseasesPancreas disordersPharmaceuticalResearchUK

US DEA publishes final rule to reschedule hydrocodone combination products

US DEA publishes final rule to reschedule hydrocodone combination products

22-08-2014

The US Drug Enforcement Administration (DEA) has today published in the Federal Register the Final Rule…

AnalgesiaPharmaceuticalRegulationUS Drug Enforcement AdministrationUSA

FDA expands indication for Eliquis to treatment of DVT and PE

FDA expands indication for Eliquis to treatment of DVT and PE

22-08-2014

US pharma majors Bristol-Myers Squibb and Pfizer late yesterday said that the US Food and Drug Administration…

Boehringer IngelheimCardio-vascularEliquisPfizerPharmaceuticalPulmonary embolismRegulationUSA

Lilly’s ixekizumab shows superiority over etanercept and placebo in Ph III

Lilly’s ixekizumab shows superiority over etanercept and placebo in Ph III

21-08-2014

US pharma major Eli Lilly’s investigational medicine ixekizumab was superior to etanercept and placebo…

Eli LillyInflammatory diseasesixekizumabPharmaceuticalRegulationResearch

26 to 35 of 95916 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top